Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00972075
Other study ID # CIRCADIN 1
Secondary ID
Status Completed
Phase Phase 2
First received September 3, 2009
Last updated September 6, 2009
Start date February 2006
Est. completion date October 2007

Study information

Verified date September 2009
Source Neurim Pharmaceuticals Ltd.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The aim of this placebo-controlled randomized study was to evaluate the efficacy of Circadin™ 2 mg in improving total night sleep duration and stabilizing the circadian clock phase in totally blind subjects with non-24 hour sleep-wake disorder.


Description:

This was a multi-center, double-blind, placebo-controlled study of a once-daily (QD) dose of Circadin™ 2 mg in subjects with non-24 hour sleep-wake disorder. Subjects were initially treated with placebo for 2 weeks and then were randomly assigned in a 1:1 ratio to receive Circadin™ 2 mg or placebo for 6 weeks, followed by a 2-week washout period. The primary objective was to assess the effect of Circadin 2 mg given once daily for 6 weeks on total night sleep duration. Secondary objectives were other sleep variables recorded by the diary like sleep latency, daytime naps and sleep offset time. Other endpoints were CGIC score for Severity of Illness and Global Improvement and WHO (Five) Well-Being Index score.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date October 2007
Est. primary completion date August 2007
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- Male or female subjects aged 20-80, having no conscious perception of light.

- Meeting the criteria for diagnosing Non-24h cycle in the clinical setting: 1) difficulty initiating sleep or difficulty in awakening, 2) progressive delay of sleep phase with inability to maintain entrainment to 24-hour-day, and 3) presence of the sleep pattern for at least six weeks.

- Average total night sleep duration of less than 6 hours per night for at least six weeks.

- Ability to ingest oral medication and participate in all scheduled evaluations.

- Signing of the Informed Consent approved by the Ethics Committee. The Informed Consent will be written in both Braille and black-and-white forms for blind subject and sighted witness.

- Education or a work history sufficient to exclude mental retardation.

- Stable medications for non-excluded concurrent medical conditions for four weeks prior to the screening visit.

Exclusion Criteria:

- Presence of medical disorders other than those related to blindness and medical treatment that may influence melatonin production, sleep or alertness. To be ascertained by medical history, complete physical examination including ECG and general biochemical work-up including complete blood count, serum chemistries, and urine analysis.

- Presence of a psychiatric or mental disorder to be assessed by a structured psychiatric interview performed by a trained individual.

- History of seizure disorders.

- Irregular lifestyle or life pattern (e.g. shift workers and patients unable to keep the study routine).

- Presence of a sleep problem revealed that may explain the subjects' complaints, such as sleep disordered breathing, restless leg syndrome or periodic limb movement syndrome.

- Use of benzodiazepines or other hypnotics during the study and preceding two weeks or 5 half lives whichever is longer.

- Known or suspected hypersensitivity to exogenous melatonin or melatonin receptor agonists

- Use of melatonin during preceding two weeks

- Use of psychiatric medications during the study and preceding three months.

- History of autoimmune diseases

- Pharmacological immuno-suppression.

- Pregnancy or lactation, child-bearing potential with a lack of adequate contraception.

- History of severe pathology likely to recur during or immediately after the study.

- Participation in a clinical trial with any investigational agent within two months prior to study enrollment.

- Patients incapable of performing the daily call to the study IVRS system and reporting on the questionnaires.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
melatonin (Circadin)
2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
placebo
one tablet per day 2 hours before going to bed

Locations

Country Name City State
United States Sleep Disorders Center of Atlanta Atlanta Georgia
United States Clinlabs, Inc. New York New York

Sponsors (1)

Lead Sponsor Collaborator
Neurim Pharmaceuticals Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total sleep time six weeks No
Secondary Daily diary records of sleep latency, sleep maintenance , total duration of naps; six weeks No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02393118 - A Study to Evaluate the BrainPort Vision Device in Individuals Blinded by Traumatic Injury N/A
Terminated NCT00262509 - Emergency Egress and Information System for Persons With Vision Loss N/A
Terminated NCT00691444 - Blind Child Melatonin Treatment Study N/A
Recruiting NCT06237829 - Testing Tactile Aids With Blind Subjects N/A
Completed NCT00829036 - Wayfinding Information Access System for People With Vision Loss N/A
Completed NCT02643238 - Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation N/A
Completed NCT01488786 - A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind N/A
Recruiting NCT00403143 - Do Blue-Blocking Lenses Block Blue Colour From Our Lives? N/A
Recruiting NCT06451172 - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis Early Phase 1
Recruiting NCT04725760 - Evaluation of the Efficacy of the BrainPort Vision Pro on the Performance of Daily Activities in the Profoundly Blind French Population N/A
Recruiting NCT02983370 - Development of a Cortical Visual Neuroprosthesis for the Blind N/A
Not yet recruiting NCT06070467 - Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
Completed NCT00920231 - Computer Vision System for the Blind Veteran Phase 1
Completed NCT01109576 - Workshops for Veterans With Vision and Hearing Loss Phase 0
Terminated NCT00795236 - Melatonin Studies of Totally Blind Children N/A
Terminated NCT00634972 - Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity Phase 4
Enrolling by invitation NCT06364605 - MySpace: the Role of Vision in Representing Space N/A
Terminated NCT03913130 - Extension Study to Study PQ-110-001 (NCT03140969) Phase 1/Phase 2
Not yet recruiting NCT05806684 - Hyperbilirubinemia and Retinopathy of Prematurity in Preterm Infants: a Retrospective Study.
Completed NCT03753893 - Ocular Manifestations in Rheumatic Diseases